Advanced Medical Solutions Grp PLC Notice of Results (1035R)
March 04 2021 - 1:00AM
UK Regulatory
TIDMAMS
RNS Number : 1035R
Advanced Medical Solutions Grp PLC
04 March 2021
04 March 2021
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Notice of Preliminary Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the surgical and advanced wound care specialist company, will
announce its preliminary results for the twelve months ended 31
December 2020 on Wednesday, 17 March 2021.
A virtual briefing for analysts will be held at 9:30am GMT on
the day of the results. For more information on the conference
call, please contact AMS@consilium-comms.com.
- End -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Olivia
Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Patrick Robb / Gary Clarence
About Advanced Medical Solutions Group plc
AMS is a world-leading developer and manufacturer of innovative
and technologically advanced products for the global surgical and
woundcare markets, focused on quality outcomes for patients and
value for payers. AMS has a wide range of surgical products
including tissue adhesives, sutures, haemostats, and internal
fixation devices, which it markets under its brands LiquiBand(R) ,
RESORBA(R) , and LiquiBandFix8(R) . AMS also supplies wound care
dressings such as silver alginates, alginates and foams through its
ActivHeal(R) brand as well as under white label. In 2019, the Group
made two acquisitions: Sealantis, an Israeli medical device company
with a patent-protected sealant technology platform; and
Biomatlante, an established developer and manufacturer of
innovative surgical biomaterial technologies based in France. In
2020, the Group acquired Raleigh Adhesive Coatings, a leading
coater and converter of materials predominately for woundcare and
bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has approximately 700 employees. For more information, please see
www.admedsol.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFZGGFMFVGMZZ
(END) Dow Jones Newswires
March 04, 2021 02:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024